Your Messages Inbox
Your Article Summary
See Latest ArticlesPhase I Trial of Pazopanib in Patients with Advanced Cancer
Clinical Cancer Research, 06/25/09
Hurwitz HI et al. - Pazopanib was generally well tolerated and showed antitumor activity across various tumor types. A monotherapy dose of 800 mg once daily was selected for phase II studies.
Related Articles
GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for VOTRIENT
GlaxoSmithKline, 10/06/09
Relevance Score: 80%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Intravenous Drug Administration During Out-of-Hospital Cardiac Arrest: A Randomized Trial
JAMA, 11/25/09
A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimers disease: a post hoc analysis
Current Medical Research and Opinion, 11/25/09
Pandemic 2009 Influenza Update: Pandemrix data in children and adolescents from 3 to 17 years of age
GlaxoSmithKline, 11/24/09
Article Search
Sponsor